These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 678388)

  • 1. Plasma protein binding of propranolol and isoprenaline in hyperthyroidism and hypothyroidism.
    Kelly JG; McDevitt DG
    Br J Clin Pharmacol; 1978 Aug; 6(2):123-7. PubMed ID: 678388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma propranolol steady state concentrations in thyroid disorders.
    Feely J; Crooks J; Stevenson IH
    Eur J Clin Pharmacol; 1981; 19(5):329-33. PubMed ID: 7238561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered plasma protein binding of drugs in thyroid disease.
    Feely J; Stevenson IH; Crooks J
    Clin Pharmacokinet; 1981; 6(4):298-305. PubMed ID: 7249488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration.
    Feely J; Crooks J; Stevenson IH
    Br J Clin Pharmacol; 1981 Jul; 12(1):73-8. PubMed ID: 6264937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma atriopeptin concentrations in hyperthyroidism, euthyroidism, and hypothyroidism: studies in man and rat.
    Ladenson PW; Langevin H; Michener M
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1172-6. PubMed ID: 2960689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catecholamine sensitivity in hyperthyroidism and hypothyroidism.
    McDevitt DG; Riddell JG; Hadden DR; Montgomery DA
    Br J Clin Pharmacol; 1978 Oct; 6(4):297-301. PubMed ID: 698027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.
    Ozkaya M; Sahin M; Cakal E; Yuzbasioglu F; Sezer K; Kilinc M; Imrek SS
    J Endocrinol Invest; 2009 May; 32(5):435-9. PubMed ID: 19498324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lipoprotein (a) concentrations in hypothyroid, euthyroid and hyperthyroid subjects.
    Erem C; Değer O; Bostan M; Orem A; Sönmez M; Ulusoy S; Telatar M
    Acta Cardiol; 1999 Apr; 54(2):77-81. PubMed ID: 10378018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cyclic AMP response to glucagon as an index of tissue responsiveness to thyroid hormone.
    Paisey R; Elkeles RS; Hambley J; Belchetz PE
    Diabete Metab; 1978 Dec; 4(4):267-70. PubMed ID: 215472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth hormone/insulin-like growth factor axis in patients with subclinical thyroid dysfunction.
    Akin F; Yaylali GF; Turgut S; Kaptanoglu B
    Growth Horm IGF Res; 2009 Jun; 19(3):252-5. PubMed ID: 19111490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual plasma ghrelin changes in the same patients in hyperthyroid, hypothyroid and euthyroid state.
    Ruchala M; Gurgul E; Stangierski A; Wrotkowska E; Moczko J
    Peptides; 2014 Jan; 51():31-4. PubMed ID: 24184592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinol Binding Protein-4 and Adiponectin Levels in Thyroid Overt and Subclinical Dysfunction.
    Kokkinos S; Papazoglou D; Zisimopoulos A; Papanas N; Tiaka E; Antonoglou C; Maltezos E
    Exp Clin Endocrinol Diabetes; 2016 Feb; 124(2):87-92. PubMed ID: 26575118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in plasma low-density lipoprotein (LDL)- and high-density lipoprotein cholesterol in hypo- and hyperthyroid patients are related to changes in free thyroxine, not to polymorphisms in LDL receptor or cholesterol ester transfer protein genes.
    Diekman MJ; Anghelescu N; Endert E; Bakker O; Wiersinga WM
    J Clin Endocrinol Metab; 2000 May; 85(5):1857-62. PubMed ID: 10843165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in plasma homocysteine levels of rats with experimentally induced hypothyroidism and hyperthyroidism.
    Ozkan Y; Dönder E; Güney H; Baydaş G
    Neuro Endocrinol Lett; 2005 Oct; 26(5):536-40. PubMed ID: 16264404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of thyroid dysfunction on propranolol kinetics.
    Riddell JG; Neill JD; Kelly JG; McDevitt DG
    Clin Pharmacol Ther; 1980 Nov; 28(5):565-74. PubMed ID: 7438675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of isoproterenol on phospholamban-deficient mouse hearts with altered thyroid conditions.
    Brittsan AG; Kiss E; Edes I; Grupp IL; Grupp G; Kranias EG
    J Mol Cell Cardiol; 1999 Sep; 31(9):1725-37. PubMed ID: 10471356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenergic modulation of insulin secretion in vivo dependent on thyroid states.
    Okajima F; Ui M
    Am J Physiol; 1978 Feb; 234(2):E106-11. PubMed ID: 623287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catecholamine metabolism in thyroid disease. II. Norepinephrine secretion rate in hyperthyroidism and hypothyroidism.
    Coulombe P; Dussault JH; Walker P
    J Clin Endocrinol Metab; 1977 Jun; 44(6):1185-9. PubMed ID: 874048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of surgery on plasma propranolol levels and protein binding.
    Feely J; Forrest A; Gunn A; Hamilton W; Stevenson I; Crooks J
    Clin Pharmacol Ther; 1980 Dec; 28(6):759-64. PubMed ID: 7438691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of thyroid dysfunction on serum cystatin C.
    Fricker M; Wiesli P; Brändle M; Schwegler B; Schmid C
    Kidney Int; 2003 May; 63(5):1944-7. PubMed ID: 12675875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.